Acromegaly is a complex systemic disorder caused by the persistent overproduction of growth hormone, usually by a benign pituitary tumour. While the most visible signs involve the enlargement of the hands, feet, and facial features, the most significant clinical risks are internal. The chronic excess of growth hormone and its secondary mediator, insulin like growth factor 1 (IGF 1), profoundly impacts the body’s metabolic and cardiovascular systems. In the United Kingdom, managing acromegaly is not merely about treating the tumour itself but also about addressing the substantial increase in the risk of developing type 2 diabetes and various forms of heart disease. Understanding the physiological mechanisms behind these risks is essential for patients to coordinate their long term care and reduce the potential for life limiting complications.
What We’ll Discuss in This Article
- How growth hormone excess causes insulin resistance and diabetes.
- The direct impact of IGF 1 on the structure and function of the heart.
- The prevalence of hypertension (high blood pressure) in acromegaly patients.
- Metabolic changes and the risk of dyslipidaemia (high cholesterol).
- Long term cardiovascular complications like cardiomyopathy and heart failure.
- The role of biochemical control in reversing metabolic and cardiac risks.
- Answers to common questions regarding heart and blood sugar monitoring.
The link between growth hormone and insulin resistance
Growth hormone plays a primary role in regulating the body’s metabolism, but in excess, it interferes with the way the body handles sugar. Growth hormone is inherently “diabetogenic,” meaning it actively opposes the action of insulin. Under normal conditions, insulin helps cells absorb glucose from the blood to be used for energy. However, high levels of growth hormone stimulate the liver to produce more glucose while simultaneously making the muscles and fat tissues less responsive to insulin. This state is known as insulin resistance.
As the body struggles to overcome this resistance, the pancreas must work harder to produce more insulin. Eventually, the pancreas can no longer keep up with the demand, leading to elevated blood sugar levels. Statistics from the Society for Endocrinology indicate that approximately 50 percent of patients with acromegaly have impaired glucose tolerance, and up to 25 to 30 percent develop full type 2 diabetes. In the UK, a HbA1c blood test is a standard part of the diagnostic and follow up process for all acromegaly patients to monitor this metabolic disruption.
Acromegaly and the development of heart disease
The cardiovascular system is particularly sensitive to the effects of growth hormone and IGF 1. Chronic exposure to these hormones causes the cells of the heart muscle, known as myocytes, to increase in size and number. This leads to a condition called left ventricular hypertrophy, where the walls of the heart become thickened and stiff. This structural change makes it more difficult for the heart to pump blood effectively and can eventually lead to a specific type of heart failure.
| Cardiovascular Condition | Prevalence in Acromegaly | Clinical Impact |
| Hypertension | 35% to 50% | Increases risk of stroke and heart attack |
| Left Ventricular Hypertrophy | Up to 70% | Leads to stiffening of the heart muscle |
| Valvular Heart Disease | 20% to 30% | Causes “leaky” heart valves, primarily aortic and mitral |
| Arrhythmias | Common | Irregular heartbeats, often due to tissue scarring |
According to clinical data published in the British Journal of Cardiology, acromegalic cardiomyopathy is a distinct form of heart disease that progresses through stages. Initially, the heart may pump more blood than normal, but over time, the thickening of the muscle and the development of fibrous (scar) tissue lead to a decline in function. Early intervention to normalize hormone levels is the most effective way to halt or even partially reverse these structural changes.
Hypertension and its management in pituitary disease
High blood pressure, or hypertension, is one of the most common complications associated with acromegaly in the United Kingdom. It is thought to be caused by a combination of factors, including increased salt and water retention by the kidneys and changes in the elasticity of the blood vessels. Growth hormone directly stimulates the kidneys to reabsorb sodium, which increases the overall volume of fluid in the circulatory system, putting extra pressure on the arterial walls.
If left untreated, hypertension significantly increases the risk of stroke, kidney damage, and coronary artery disease. In the UK, NICE guidelines recommend that blood pressure should be monitored at every specialist appointment. Treatment for hypertension in acromegaly patients often requires a combination of standard blood pressure medications and specific treatments aimed at lowering the growth hormone levels. Interestingly, once the pituitary tumour is successfully treated, many patients find that their blood pressure improves significantly, sometimes allowing for a reduction in their medication.
The risk of sleep apnoea and its cardiac impact
Sleep apnoea is a condition where breathing repeatedly stops and starts during sleep, and it is highly prevalent in acromegaly, affecting up to 70 percent of patients. The excess growth hormone causes the soft tissues in the throat and the tongue to enlarge, which can physically block the airway during sleep. This condition is not just a cause of tiredness; it places an immense strain on the heart and lungs.
Each time a person stops breathing during the night, their oxygen levels drop, and their heart rate and blood pressure spike. This chronic nightly stress contributes to the development of hypertension and right sided heart failure. In the UK, patients with acromegaly are frequently referred for a sleep study (polysomnography) to assess the severity of their apnoea. Treating sleep apnoea with a CPAP machine (Continuous Positive Airway Pressure) not only improves energy levels but also significantly reduces the long term cardiovascular risk associated with pituitary hormone excess.
Metabolic changes: Cholesterol and lipid levels
Growth hormone excess also disrupts the body’s ability to process fats, leading to dyslipidaemia. Many patients with acromegaly have elevated levels of triglycerides and low levels of “good” HDL cholesterol. These metabolic changes contribute to the development of atherosclerosis, where fatty plaques build up in the arteries, increasing the risk of heart attacks and peripheral vascular disease.
The combination of diabetes, hypertension, and high cholesterol creates a “perfect storm” for cardiovascular health. This is why UK endocrine centres adopt a multidisciplinary approach, often involving dietitians and cardiologists in the care of acromegaly patients. Regular blood tests to check the lipid profile are essential. Managing these metabolic markers through diet, exercise, and sometimes statin therapy is a cornerstone of preventing the long term complications of the disease.
Reversing the risks through biochemical control
The primary goal of treating acromegaly in the UK is to achieve “biochemical control,” which means bringing growth hormone and IGF 1 levels back into the normal range. When this is achieved whether through surgery, medication, or radiotherapy the metabolic and cardiovascular risks begin to decline. Studies have shown that early treatment can lead to a significant reduction in heart muscle thickness and an improvement in insulin sensitivity.
For many patients, the diagnosis of diabetes or hypertension is what finally leads to the discovery of their acromegaly. While some of the bone changes caused by the disease are permanent, many of the soft tissue and metabolic changes are reversible. Data from the UK Acromegaly Register demonstrates that patients who achieve stable hormone levels have a life expectancy that is comparable to the general population. This highlights the critical importance of long term follow up and adherence to treatment to protect the heart and the body’s metabolic health.
Conclusion
Acromegaly significantly increases the risk of diabetes and heart disease due to the direct and indirect effects of growth hormone and IGF 1 excess. The hormone surplus causes insulin resistance, leading to type 2 diabetes, and triggers structural changes in the heart muscle that can result in hypertension and cardiomyopathy. Additionally, complications like sleep apnoea and lipid imbalances further strain the cardiovascular system. Achieving biochemical control through specialized UK medical care is essential to manage these risks and improve long term health outcomes. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Will my diabetes go away if my acromegaly is treated?
In many cases, blood sugar levels improve significantly once hormone levels are normalized; some patients may even be able to stop their diabetes medication, though others may require long term management.
Why does acromegaly cause high blood pressure?
The hormone excess causes the kidneys to retain more salt and water, increasing blood volume, while also causing the blood vessels to become less flexible.
How often should I have my heart checked?
In the UK, it is standard for acromegaly patients to have an electrocardiogram and sometimes an echocardiogram at diagnosis and then periodically based on their symptoms and hormone levels.
Can acromegaly cause a heart attack?
While not a direct cause, the increased risks of diabetes, hypertension, and high cholesterol associated with acromegaly can accelerate the development of coronary artery disease.
Is the heart damage from acromegaly permanent?
Soft tissue thickening in the heart can often be partially or fully reversed with early treatment, but long term scarring of the heart tissue may be permanent.
Does everyone with acromegaly get diabetes?
No, but a large proportion (up to 50 percent) develop some form of impaired glucose tolerance or full type 2 diabetes.
What is the “gold standard” for checking my blood sugar in the UK?
The HbA1c test is typically used to monitor average blood sugar over the previous three months, providing a clear picture of metabolic control.
Authority Snapshot (E-E-A-T Block)
This article provides a clinical overview of the relationship between acromegaly, diabetes, and heart disease to support patient education. The content has been authored by a specialized medical content team and reviewed by Dr. Rebecca Fernandez to ensure the highest standards of accuracy and safety. All information presented is strictly aligned with the latest NHS guidelines and UK endocrine society standards to provide reliable information for patients in the United Kingdom.
